Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway. - Jiang, Zhixiong; Yang, Yating; Zhou, Jinchi; Li, Xin; Meng, Qingqing; Yu, Xiangyi; Xue, Yaxin; Li, Mengyu; Cai, Yichen; Han, Pengchun; Jiang, Mingjun; Wang, Huizhen; et al. (Journal of Translational Medicine, 2025)